Solazyme (Nasdaq: SZYM) reported earnings on Feb. 20. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Dec. 31 (Q4), Solazyme missed estimates on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue shrank significantly. Non-GAAP loss per share grew. GAAP loss per share increased.

Margins contracted across the board.

Revenue details
 Solazyme tallied revenue of $8.4 million. The 10 analysts polled by S&P Capital IQ foresaw revenue of $8.9 million on the same basis. GAAP reported sales were 43% lower than the prior-year quarter's $14.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at -$0.35. The four earnings estimates compiled by S&P Capital IQ predicted -$0.31 per share. Non-GAAP EPS were -$0.35 for Q4 versus -$0.26 per share for the prior-year quarter. GAAP EPS were -$0.40 for Q4 against -$0.26 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 83.3%, 1,110 basis points worse than the prior-year quarter. Operating margin was -296.5%, 19,110 basis points worse than the prior-year quarter. Net margin was -292.1%, 18,750 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $13.1 million. On the bottom line, the average EPS estimate is -$0.30.

Next year's average estimate for revenue is $79.8 million. The average EPS estimate is -$1.15.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 368 members out of 386 rating the stock outperform, and 18 members rating it underperform. Among 85 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 78 give Solazyme a green thumbs-up, and seven give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Solazyme is outperform, with an average price target of $17.08.

Is Solazyme the right energy stock for you? Read about a handful of timely, profit-producing plays on expensive crude in "3 Stocks for $100 Oil." Click here for instant access to this free report.